[Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)].
D000368:Aged; D001545:Benserazide / Q000494:pharmacology / Q000627:therapeutic use; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D004295:Dihydroxyphenylalanine / Q000494:pharmacology / Q000627:therapeutic use*; D004341:Drug Evaluation; D004576:Electromyography; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D008875:Middle Aged; D009127:Muscle Rigidity / Q000175:diagnosis / Q000188:drug therapy*; D009129:Muscle Tonus / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy* / Q000601:surgery; D013238:Stereotaxic Techniques
D006834:Hydrazines; D004295:Dihydroxyphenylalanine; D001545:Benserazide; D002262:Carboxy-Lyases
Quantitative Rigormessung bei Morbus Parkinson. Myointegration zur Therapiekontrolle von L-Dopa in Kombination mit einem Decarboxylasehemmer (Ro 8-0576)